Sanuwave Health Financial Results
SANUWAVE Health reported Q3 2026 revenue of $8.6 million, a 24% decrease year-over-year, primarily driven by a significant drop in Ultramist system sales. The company posted a net loss of $1.4 million for the quarter, compared to net income of $9.7 million in the prior year, which had benefited from one-time gains. Management attributed the performance to market uncertainty surrounding proposed CMS rule changes affecting wound care reimbursement.
- Term
- Q3 2026
“Q3 was very much the story of the CMS proposed rule. This affected Sanuwave in multiple ways. The proposal to maintain skin substitute pricing at 2026 levels for 2027 caused a number of mobile wound care practitioners, particularly those providing rural home care, to exit some or all of their operations.”
Morgan Frank, CEO